Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance

Cancer Letters

Volumn 341, Issue 1, 2013, Pages 56-62

  Pinto, Cletus A ^a,b   Widodo, Edwin ^a,b   Waltham, Mark ^a,b   Thompson, Erik W ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemoresistance; Epithelial mesenchymal plasticity; Stem Cells

Indexed keywords

DOXORUBICIN; PACLITAXEL; SALINOMYCIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR SPACE; GENE MUTATION; HUMAN; MESENCHYME CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 84887186929     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.003     Document Type: Review

References (109)

1. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
2. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nature Reviews Cancer 2012, 12:323-334.
3. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
4. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. International Journal of Cancer 2011, 129:2310-2314.
5. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer 2008, 8:755-768.
6. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. New England Journal of Medicine 2006, 355:1253-1261.
7. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annual Review of Medicine 2007, 58:267-284.
8. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., Polyak K. Molecular definition of breast cancer tumor heterogenity. Cancer Cell 2007, 11:259-273.
9. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2009, 1796:75-90.
10. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
11. Behbod F., Rosen J.M. Will cancer stem cells provide new therapeutic targets?. Carcinogenesis 2005, 26:703-711.
12. Seigel G.M., Campbell L.M., Narayan M., Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Molecular Vision 2005, 11:729-737.
13. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Reviews Cancer 2005, 5:744-749.
14. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research 2005, 65:5506-5511.
15. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
16. Chang C.C. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Research 2006, 8:103-106.
17. Al-Hajj M., Becker M., Wicha M., Weissman I., Clarke M. Therapeutic implications of cancer stem cells. Current Opinion in Genetics and Development 2004, 14:43-47.
18. Al-Hajj M., Wicha M., Benito-Hernandez A., Morrison S., Clarke M. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences 2003, 100:3983-3988.
19. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K., Clarke M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. The New England Journal of Medicine 2007, 356:217-226.
20. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences 2009, 106:13820-13825.
21. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
22. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S., Weinberg R., Neve R., Lenburg M., Thompson E. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44hi&CD24lo/- stem cell phenotype in human breast cancer. Journal of Mammary Gland Biology and Neoplasia 2010, 15:235-252.
23. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
24. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences 2011, 108:7950-7955.
25. Chaffer C.L., Thompson E.W., Williams E.D. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007, 185:7-19.
26. Hay E. An overview of epithelio-mesenchymal transformation. Cells Tissues Organs 1995, 154:8-20.
27. Hugo H., Ackland M.L., Blick T., Lawrence M.G., Clements J.A., Williams E.D., Thompson E.W. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. Journal of Cellular Physiology 2007, 213:374-383.
28. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. Cell Biology 2006, 172:973-981.
29. Schor S.L. Cell proliferation and migration on collagen substrata in vitro. Journal of Cell Science 1980, 41:159-175.
30. Savagner P., Boyer B., Valles A., Jouanneau J., Thiery J. Modulations of the epithelial phenotype during embryogenesis and cancer progression. Cancer Treatment and Research 1994, 71:229-249.
31. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006, 7:131-142.
32. Hugo H., Ackland M.L., Blick T., Lawrence M.G., Clements J.A., Williams E.D., Thompson E.W. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. Journal of Cell Physiology 2007, 213:374-383.
33. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
34. Sommers C.L., Heckford S.E., Skerker J.M., Worland P., Torri J.A., Thompson E.W., Byers S.W., Gelmann E.P. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Research 1992, 52:5190-5197.
35. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
36. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 2009, 119:1420-1428.
37. Kasai H., Allen J.T., Mason R.M., Kamimura T., Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respiratory Research 2005, 6:56.
38. Prindull G., Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 2004, 103:2892-2899.
39. Thompson E.W., Newgreen D.F. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Research 2005, 65:5991-5995.
40. Zavadil J., Böttinger E.P. TGF-ß and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774.
41. Chiarugi P., Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochemical Pharmacology 2008, 76:1352-1364.
42. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
43. Przybylo J.A., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. International Journal of Biochemistry and Cell Biology 2007, 39:1082-1088.
44. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Research 2005, 65:9455-9462.
45. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
46. Gradilone A., Raimondi C., Nicolazzo C., Petracca A., Gandini O., Vincenzi B., Naso G., Aglianò A.M., Cortesi E., Gazzaniga P. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. Journal of Cellular and Molecular Medicine 2011, 15:1066-1070.
47. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., Herold C.I., Marcom P.K., George D.J., Garcia-Blanco M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 2011, 9:997-1007.
48. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer and Metastasis Reviews 2012, 1-15.
49. Gradilone A., Naso G., Raimondi C., Cortesi E., Gandini O., Vincenzi B., Saltarelli R., Chiapparino E., Spremberg F., Cristofanilli M. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology 2011, 22:86-92.
50. Bonnomet A., Brysse A., Tachsidis A., Waltham M., Thompson E.W., Polette M., Gilles C. Epithelial-to-mesenchymal transitions and circulating tumor cells. Journal of Mammary Gland Biology and Neoplasia 2010, 15:261-273.
51. Willipinski-Stapelfeldt B., Riethdorf S., Assmann V., Woelfle U., Rau T., Sauter G., Heukeshoven J., Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clinical Cancer Research 2005, 11:8006-8014.
52. Bonnomet A., Syne L., Brysse A., Feyereisen E., Thompson E., Noël A., Foidart J.M., Birembaut P., Polette M., Gilles C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2011, 1-13.
53. Chao Y.L., Shepard C.R., Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Molecular Cancer 2010, 9:179.
54. Gorges T.M., Tinhofer I., Drosch M., Roese L., Zollner T.M., Krahn T., von Ahsen O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC cancer 2012, 12:178.
55. Alix-Panabières C., Riethdorf S., Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clinical Cancer Research 2008, 14:5013-5021.
56. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research 2009, 11:R46.
57. Raimondi C., Gradilone A., Naso G., Vincenzi B., Petracca A., Nicolazzo C., Palazzo A., Saltarelli R., Spremberg F., Cortesi E., Gazzaniga P. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research Treatment 2011, 130:449-455.
58. Kasimir-Bauer S., Hoffmann O., Wallwiener D., Kimmig R., Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Research 2012, 14:R15.
59. Celià-Terrassa T., Meca-Cortés Ó., Mateo F., Martínez de Paz A., Rubio N., Arnal-Estapé A., Ell B.J., Bermudo R., Díaz A., Guerra-Rebollo M., Lozano J.J., Estarás C., Ulloa C., lvarez-Simón D., Milà J., Vilella R., Paciucci R., Martínez-Balbás M., García de Herreros A., Gomis R.R., Kang Y., Blanco J., Fernández P.L., Thomson T.M. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. The Journal of Clinical Investigation 2012, 122:1849-1868.
60. Rodríguez-Pinilla S.M., Sarrió D., Honrado E., Moreno-Bueno G., Hardisson D., Calero F., Benítez J., Palacios J. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. Journal of Clinical Pathology 2007, 60:1006-1012.
61. Santarosa M., Maestro R. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Cancer and Metastasis Reviews 2011, 31:131-142.
62. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303.
63. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.-L., Gyorki D.E., Ward T., Partanen A., Feleppa F., Huschtscha L.I., Thorne H.J., Fox S.B., Yan M., French J.D., Brown M.A., Smyth G.K., Visvader J.E., Lindeman G.J. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 2009, 15:907-913.
64. Proia T.A., Keller P.J., Gupta P.B., Klebba I., Jones A.D., Sedic M., Gilmore H., Tung N., Naber S.P., Schnitt S. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163.
65. Liu X., Holstege H., Van Der Gulden H., Treur-Mulder M., Zevenhoven J., Velds A., Kerkhoven R.M., Van Vliet M.H., Wessels L.F.A., Peterse J.L. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences 2007, 104:12111-12116.
66. Molyneux G., Geyer F.C., Magnay F.A., McCarthy A., Kendrick H., Natrajan R., MacKay A., Grigoriadis A., Tutt A., Ashworth A. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
67. Gastaldi S., Sassi F., Accornero P., Torti D., Galimi F., Migliardi G., Molyneux G., Perera T., Comoglio P.M., Boccaccio C., Smalley M.J., Bertotti A., Trusolino L. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene 2012, 1-13.
68. Kim J., Villadsen R., Sørlie T., Fogh L., Grønlund S.Z., Fridriksdottir A.J., Kuhn I., Rank F., Wielenga V.T., Solvang H., Edwards P.A.W., Børresen-Dale A.-L., Rønnov-Jessen L., Bissell M.J., Petersen O.W. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proceedings of the National Academy of Sciences 2012, 109:6124-6129.
69. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes and Development 2009, 23:2563-2577.
70. DiMeo T.A., Anderson K., Phadke P., Fan C., Perou C.M., Naber S., Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Research 2009, 69:5364-5373.
71. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., Itzkovitz S., Noske A., Zurrer-Hardi U., Bell G., Tam W.L., Mani S.A., van Oudenaarden A., Weinberg R.A. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
72. Zhang J., Liang Q., Lei Y., Yao M., Li L., Gao X., Feng J., Zhang Y., Gao H., Liu D.X., Lu J., Huang B. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Research 2012, 72:4597-4608.
73. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 2010, 12:R68.
74. Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2010, 15:253-260.
75. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences 2010, 107:15449-15454.
76. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adélaïde J., Cervera N., Fekairi S., Xerri L., Jacquemier J., Birnbaum D. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284.
77. Sarrio D., Rodriguez-Pinilla S., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 2008, 68:989-997.
78. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical and Experimental Metastasis 2008, 25:629-642.
79. Herschkowitz J.I., Zhao W., Zhang M., Usary J., Murrow G., Edwards D., Knezevic J., Greene S.B., Darr D., Troester M.A. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proceedings of the National Academy of Sciences 2012, 109:2778-2783.
80. Hennessy B., Giordano S., Broglio K., Duan Z., Trent J., Buchholz T., Babiera G., Hortobagyi G., Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Annals of Oncology 2006, 17:605-613.
81. Hennessy B.T., Gonzalez-Angulo A.-M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.-S., Fridlyand J., Sahin A., Agarwal R., Joy C., Liu W., Stivers D., Baggerly K., Carey M., Lluch A., Monteagudo C., He X., Weigman V., Fan C., Palazzo J., Hortobagyi G.N., Nolden L.K., Wang N.J., Valero V., Gray J.W., Perou C.M., Mills G.B. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 2009, 69:4116-4124.
82. Fulda S. Tumor resistance to apoptosis. International Journal of Cancer 2009, 124:511-515.
83. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews 2008, 34:378-390.
84. Saunders N.A., Simpson F., Thompson E.W., Hill M.M., Endo-Munoz L., Leggatt G., Minchin R.F., Guminski A. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO molecular medicine 2012, 4:675-684.
85. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of The National Cancer Institute 2008, 100:672-679.
86. Ahmed N., Abubaker K., Findlay J., Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets 2010, 10:268-278.
87. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., Hur M.H., Diebel M.E., Monville F., Dutcher J. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Research 2009, 69:1302-1313.
88. Hollier B.G., Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia 2009, 14:29-43.
89. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
90. Tiligada E. Chemotherapy: induction of stress responses. Endocrine-Related Cancer 2006, 13:S115-S124.
91. Li Q.-Q., Xu J.-D., Wang W.-J., Cao X.-X., Chen Q., Tang F., Chen Z.-Q., Liu X.-P., Xu Z.-D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clinical Cancer Research 2009, 15:2657-2665.
92. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., Andre S., Piccart M., Campone M., Brain E., MacGrogan G., Petit T., Jassem J., Bibeau F., Blot E., Bogaerts J., Aguet M., Bergh J., Iggo R., Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine 2009, 15:68-74.
93. Kajita M., McClinic K.N., Wade P.A. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Molecular and Cellular Biology 2004, 24:7559-7566.
94. Cheng G.Z., Chan J., Wang Q., Zhang W., Sun C.D., Wang L.H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Research 2007, 67:1979-1987.
95. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., Barrow D., Nicholson R.I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. International Journal of Cancer 2006, 118:290-301.
96. Tryndyak V.P., Beland F.A., Pogribny I.P. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. International Journal of Cancer 2010, 126:2575-2583.
97. Fillmore C., Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. Breast Cancer Res 2007, 9:303.
98. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
99. Lagasse E. Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Therapy 2007, 15:136-142.
100. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nature Reviews Cancer 2005, 5:275-284.
101. Hirschmann-Jax C., Foster A., Wulf G., Nuchtern J., Jax T., Gobel U., Goodell M., Brenner M. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences 2004, 101:14228-14233.
102. Chuthapisith S., Eremin J., El-Sheemey M., Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surgical Oncology 2010, 19:27-32.
103. Steiniger S.C.J., Coppinger J.A., Krüger J.A., Yates J., Janda K.D. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 2008, 26:3037-3046.
104. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
105. Fuchs D., Heinold A., Opelz G., Daniel V., Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochemical and Biophysical Research Communications 2009, 390:743-749.
106. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., Miele L. Targeting notch to target cancer stem cells. Clinical Cancer Research 2010, 16:3141-3152.
107. Merchant A.A., Matsui W. Targeting hedgehog - a cancer stem cell pathway. Clinical Cancer Research 2010, 16:3130-3140.
108. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clinical Cancer Research 2010, 16:3153-3162.
109. Liu S., Wicha M.S. Targeting breast cancer stem cells. Journal of Clinical Oncology 2010, 28:4006-4012.